Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?

References

• McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10
   PubMed Web of Science ®Google Scholar
• Fishbane S. Anemia and cardiovascular risk in the patient with kidney disease. Heart Fail Clin 2008;4:401-10
   PubMedGoogle Scholar
• Thorp ML, Johnson ES, Yang X, et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton) 2008;14:240-6; [Epub ahead of print]
   Web of Science ®Google Scholar
• Kovesday CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006;69:560-4
   PubMed Web of Science ®Google Scholar
• Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:33-8
   PubMed Web of Science ®Google Scholar
• Valderrábano F, Hörl WH, Macdougall IC, et al. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003;18:89-100
   PubMed Web of Science ®Google Scholar
• Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008;13:393-404
   PubMed Web of Science ®Google Scholar
• Gotloib L, Silverberg D, Fudin R, et al. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006;19:161-7
   PubMed Web of Science ®Google Scholar
• Hsu C-Y, McCulloch CE, Curhan GC. Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 2002;13:2783-6
   PubMed Web of Science ®Google Scholar
• Fishbane S. Iron management in nondialysis-dependent CKD. Am J Kid Dis 2007;49:736-43
   PubMed Web of Science ®Google Scholar
• Fishbane S, Pollack S, Feldman HI, et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009;4:57-61
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Blum M, Agbaria Z, et al. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 2001;55:212-19
   PubMed Web of Science ®Google Scholar
• KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530
   Google Scholar
• Locatelli F, Covic A, Eckardt K-U, et al. on behalf of the ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009;24:348-54
   PubMed Web of Science ®Google Scholar
• Locatelli F, Aljama P, Bárány P, et al. European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1-47
   PubMedGoogle Scholar
• National Institute for Clinical Excellence (NICE). Anaemia management in people with chronic kidney disease. Clinical Guideline 39 (2006)
   Google Scholar
• KDOQI clinical practice guidelines and clinical practice recommendations for anaemia in chronic kidney disease. Am J Kidney Dis 2006;47(Suppl 3):S1-70
   Google Scholar
• Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1:S4-8
   PubMed Web of Science ®Google Scholar
• Dukkipati R, Kalantar-Zadeh K. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?. Nephrol News Issues 2007;21:34-8
   PubMedGoogle Scholar
• DeVita MV, Frumkin D, Mittal S, et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 2003;60:335-40
   PubMed Web of Science ®Google Scholar
• Agarwal AK. Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. J Am Med Dir Assoc 2006;7:S7-12
   PubMed Web of Science ®Google Scholar
• Tagboto S, Cropper L, Turner L, et al. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject®) on anaemia in a pre-dialysis population of chronic kidney disease patients. J Renal Care 2009;35:18-23
   PubMedGoogle Scholar
• Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599-1605
   PubMed Web of Science ®Google Scholar
• Tagboto S, Cropper L, Mostafa S, et al. Intravenous iron in chronic kidney disease; haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin. J Renal Care 2008;34:112-15
   PubMedGoogle Scholar
• Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006;26:445-54
   PubMed Web of Science ®Google Scholar
• Mircescu G, Gârneaţă L, Căpuşă C, et al. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006;21:120-4
   PubMed Web of Science ®Google Scholar
• Van Wyck DB, Roppolo M, Martinez CO, et al. for the United States Iron Sucrose (Venofer®) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005;68:2846-56
   PubMed Web of Science ®Google Scholar
• Anuradha S, Singh NP, Agarwal SK. Total dose infusion iron dextran therapy in predialysis chronic renal failure patients. Ren Fail 2002;24:307-13
   PubMed Web of Science ®Google Scholar
• Bhowmik D, Modi G, Ray D, et al. Total dose iron infusion: safety and efficacy in predialysis patients. Ren Fail 2000;22:39-43
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996;27:234-8
   PubMed Web of Science ®Google Scholar
• Benjamin J. A randomized controlled trial comparing IV ferric caboxymaltose (FCM) to oral iron in anemic nondialysis dependent CKD patients (with or without erythropoiesis stimulating agent use). World Congress of Nephrology 2009, Abstract M574
   Google Scholar
• Kapoian T, O’Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008;19:372-9
   PubMed Web of Science ®Google Scholar
• Fishbane S, Frei Gl, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41-6
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009;24:1082-8
   PubMed Web of Science ®Google Scholar
• Dahl NV, Henry DH, Coyne DW. Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?. Semin Dial 2008;21:210-1
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791-8
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl 1999;69:S61-6
   PubMed Web of Science ®Google Scholar
• Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997;29:319-33
   PubMed Web of Science ®Google Scholar
• Aggarwal HK, Nand N, Singh S, et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 2003;51:170-4
   PubMedGoogle Scholar
• Charytan C, Qunibi W, Bailie GR; for the Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005;100:c55-62
   PubMed Web of Science ®Google Scholar
• Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001;16:967-74
   PubMed Web of Science ®Google Scholar
• Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008;52:897-906
   PubMed Web of Science ®Google Scholar
• Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980;243:1726-31
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 2009;16:117-30
   PubMed Web of Science ®Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-82
   PubMed Web of Science ®Google Scholar
• Bailie GR, Clark JA, Lane CE, et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005;20:1443-9
   PubMed Web of Science ®Google Scholar
• Qunibi WY, Martinez C, Smith M, et al. Efficacy and safety of IV ferric carboxymaltose (FCM) compared to oral iron in anemic patients with non-dialysis-dependent CKD. XLV ERA-EDTA Congress, 10-13 May 2008, Stockholm, Sweden. Abstract MO018
   Google Scholar
• Qunibi WY, Benjamin J. Safety and tolerability profile of ferric carboxymaltose (FCM), a new high dose IV iron, across ten multi-center clinical trials. XLV ERA-EDTA Congress, 10-13 May 2008, Stockholm, Sweden. Abstract MP383
   Google Scholar
• Toblli JE, Cao G, Oliveri L, et al. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. American Society of Nephrology (ASN) Renal Week Congress, October 29–November 1 2009, San Diego, USA. Abstract SA-PO2702
   Google Scholar
• Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005;46:283-9
   PubMed Web of Science ®Google Scholar
• Ferinject Summary of Product Characteristics. Last updated July 2007
   Google Scholar
• Choy CK, Spencer AP, Nappi JM. Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment. Pharmacotherapy 2007;27:707-14
   PubMed Web of Science ®Google Scholar
• Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 2008;52:501-11
   PubMed Web of Science ®Google Scholar
• Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103-12
   PubMed Web of Science ®Google Scholar
• Toblli JE, Lombraña A, Duarte P, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657-65
   PubMed Web of Science ®Google Scholar
• Anker SD, Colet JC, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361; [Epub ahead of print]
   Google Scholar
• Kulnigg S, Gasche C. Systemic review: managing anaemia in Crohn’s disease. Aliment Pharmacol Ther 2006;24:1507-23
   PubMed Web of Science ®Google Scholar
• Lindgren W, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009;27:1-8; [Epub ahead of print]
   Google Scholar
• Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-92
   PubMed Web of Science ®Google Scholar
• Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007;110:267-78
   PubMed Web of Science ®Google Scholar
• Westad S, Backe B, Salvesen KA, et al. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia. Acta Obstet Gynecol Scand 2008;87:916-23
   PubMed Web of Science ®Google Scholar
• Kim YH, Chung HH, Kang SB, et al. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study. Acta Haematol 2009;121:37-41
   PubMed Web of Science ®Google Scholar
• www.clinicaltrials.gov, clinical trial NCT00830037 (Accessed 15 October 2009)
   Google Scholar
• Macdougall IC, Bock A, Carrera F, et al. Rationale and design of a new RCT of iron therapy in anemic non-dialysis CKD patients: FIND-CKD trial. American Society of Nephrology (ASN) Renal Week Congress, October 29-November 1 2009, San Diego, USA. Abstract SA-PO2402
   Google Scholar